BiSiChem is developing TGF-β inhibitors as a candidate for solid tumors and/or immunotherapy
and applied for the PCT international patent in 2020.
TGF-β Inhibitor relates to a series of substituted heterocyclic compounds which are inhibitors
of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4).
The inhibitor plays a key role in improving the surrounding environment to ensure that immune cells attack cancer cells.
In normal cells, TGF-β plays a crucial role in the maintenance of cell homeostasis and organ formation,
including cell growth & death, differentiation, immunity and epithelial-mesenchymal transition(EMT)
in various biological processes.
However, abnormal signal transduction of TGF-β causes life-threatening diseases such as cancer, fibrosis,
NASH, and diabetes. Especially in the tumor micro environment, it suppresses immunity, promotes cancer cell metastasis,
and induces anti-cancer drugs resistance.